Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas

Biernat, W.; Debiec-Rychter, M.; Liberski, P.P.

Polish Journal of Pathology Official Journal of the Polish Society of Pathologists 49(4): 267-271

1998

ISSN/ISBN: 1233-9687
PMID: 10323080
Document Number: 7181
We investigated the frequency and mutual relationship of molecular alterations in 33 malignant astrocytomas (28 glioblastomas and 5 anaplastic astrocytomas). The genetic alterations analyzed were: deletion of CDKN2a/p16 gene, TP53 mutations, and amplification of EGFR, MDM2 and CDK4. The most common genetic alteration was EGFR amplification which was revealed in 15 cases (45%). TP53 mutation was identified in 9 cases (27%) and CDKN2/p16 deletion was detected in 13 cases (41%). Either MDM2 and CDK4 amplifications were less frequent, as they were identified in 4 (12%) and 1 (3%) case, respectively. Of the 15 cases showing the amplification of EGFR, 9 had CDKN2/p16 deletion (60%, p = 0.04). On the other hand, CDKN2/p16 deletion and EGFR amplification rarely occurred with TP53 mutations (2 of 14 cases with CDKN2/p16 deletion, 14%). These results confirm the existence of at least two different pathways leading to the formation of a glioblastoma.

Document emailed within 1 workday
Secure & encrypted payments

Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas

Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Jin, B.; Zhang, Y.; Zhang, X.; Li, R.; Lou, Y.; Niu, Y.; Huang, A.; Han, B. 2014: Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKi in advanced non-small cell lung cancer harboring EGFR mutations Zhonghua Yi Xue Za Zhi 94(30): 2327-2331
El Hamdani, W.; Amrani, M.; Attaleb, M.; Laantri, N.; Ennaji, M.M.; Khyatti, M.; El Mzibri, M. 2010: EGFR, p16INK4a and E-cadherin immuno-histochemistry and EGFR point mutations analyses in invasive cervical cancer specimens from Moroccan women Cellular and Molecular Biology 56 Suppl: Ol1373-Ol1384
Leong, P.K.; Thorner, P.; Yeger, H.; Ng, K.; Zhang, Z.; Squire, J. 1993: Detection of MYCN gene amplification and deletions of chromosome 1p in neuroblastoma by in situ hybridization using routine histologic sections Laboratory Investigation; A Journal of Technical Methods and Pathology 69(1): 43-50
Dong, Q.-g.; Han, B.-h.; Huang, J.-s.; Yang, L.-m.; Huang, J.; Zhao, C.-y.; Lu, L.-q. 2006: Analysis of EGFR mutations in 176 cases of non-small cell lung cancer Zhonghua Zhong Liu Za Zhi 28(9): 686-690
de Boer, J.G.; Ripley, L.S. 1988: An in vitro assay for frameshift mutations: hotspots for deletions of 1 bp by Klenow-fragment polymerase share a consensus DNA sequence Genetics 118(2): 181-191
Dahse, R.; Berndt, A.; Kosmehl, H. 2008: PCR-based testing for therapy-related EGFR mutations in patients with non-small cell lung cancer Anticancer Research 28(4b): 2265-2270
Mikhaylenko, D.S.; Sobol, I.Y.; Safronova, N.Y.; Simonova, O.A.; Efremov, E.A.; Efremov, G.D.; Alekseev, B.Y.; Kaprin, A.D.; Nemtsova, M.V. 2019: The incidence of AZF deletions, CFTR mutations and long alleles of the ar CAG repeats during the primary laboratory diagnostics in a heterogeneous group of infertily men Urologiia 3: 101-107
Von Deimling, A.; Bender, B.; Jahnke, R.; Waha, A.; Kraus, J.; Albrecht, S.; Wellenreuther, R.; Fassbender, F.; Nagel, J.; Menon, A.G. 1994: Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q Cancer Research 54(6): 1397-1401
Smir, B.N.; Hauke, R.J.; Bierman, P.J.; Gross, T.G.; d'Amore, F.; Anderson, J.R.; Greiner, T.C. 1996: Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders Laboratory Investigation; a Journal of Technical Methods and Pathology 75(4): 575-588
Guate, J.L.; Val, F.; Trigueros, F.; Dierssen, G. 1979: Postoperative survival of malignant astrocytomas within the function of their lymphocyte infiltration Revista Espanola de Oto-Neuro-Oftalmologia y Neurocirugia 37(206): 6-7
Katono, K.; Kasajima, M.; Ishihara, M.; Hayashi, N.; Nagashima, Y.; Igawa, S.; Masuda, N. 2013: A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(3): 375-377
López-Aguilar, E.; Sepúlveda Vildósola, A.C.; Rioscovián-Soto, A.P.; Gascón-Lastiri, G.; Rojas-Puentes, F.; Siordia-Reyes, G.; Diegopérez-Ramírez, J.; De la Cruz-Yáñez, H.; Barrientos-Salcedo, C. 2010: Survival of patients with malignant astrocytomas according to the expression of Ki67 antigen in a pediatric hospital Gaceta Medica de Mexico 146(2): 118-123
Benzil, D.L.; Finkelstein, S.D.; Epstein, M.H.; Finch, P.W. 1992: Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression Cancer Research 52(10): 2951-2956
Saxena, A.; Nagasaka, M.; Li, Z.; Becker, D.J.; Levy, B.P. 2014: Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer Oncology 28(6): 526; 528 530, 534
Rabbani, G.; Benzil, D.; Wallam, M.N.; Chen, B.; Hoang, A.; Kancherla, R.; Ahmed, T. 2007: Combination therapy with thalidomide, temozolomide and tamoxifen improves quality of life in patients with malignant astrocytomas Anticancer Research 27(4c): 2729-2736
Okayama, H.; Curiel, D.T.; Brantly, M.L.; Holmes, M.D.; Crystal, R.G. 1989: Rapid, nonradioactive detection of mutations in the human genome by allele-specific amplification Journal of Laboratory and Clinical Medicine 114(2): 105-113
Lewis, D.C.; Warren, N.; Shukla, V.K.; Grimshaw, D.; Laidler, P.; Padua, R.A. 1993: Gross rearrangements and deletions of the retinoblastoma gene are rare in malignant melanoma Acta Dermato-Venereologica 73(3): 236
Zhang, R.; Li, Y.; Chen, Y.; Liu, X.; Wang, Z.; Sun, H.; Zheng, Y.; Ding, Z.; Lan, L.; Li, M.; Qin, J.; Chen, X. 2015: Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer Zhonghua Yi Xue Za Zhi 95(47): 3839-3842
Tsai, M.Y.; Hanson, N.Q.; Schwichtenberg, K.; Garg, U. 1995: Amplification refractory mutation system to identify mutations in cystathionine beta-synthase deficiency Clinical Chemistry 41(12 Part 1): 1775-1777